Halozyme Therapeutics (HALO)

Common Shares
Sell: $71.88|Buy: $73.90|Change: 1.19 (-1.63%)

Company profile

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Address

11388 Sorrento Valley Road
San Diego
CA
USA
92121


Telephone

+1 858 7048222


Sector 

Healthcare


Previous key dates

NameKey Date
Halozyme Therapeutics Inc Fourth Quarter Earnings Conference Call for 20252026-02-17T16:30:00
Halozyme Therapeutics Inc Fourth Quarter Earnings Result for 20252026-02-17T00:00:00
Halozyme Therapeutics Inc Annual Report for 20252026-02-17T00:00:00
Investor Conference Call2026-01-28T08:30:00
8th Annual Evercore Healthcare Conference2025-12-02T13:20:00
Halozyme Therapeutics Inc Third Quarter Earnings Conference Call for 20252025-11-03T16:30:00
Halozyme Therapeutics Inc Third Quarter Earnings Result for 20252025-11-03T00:00:00
Morgan Stanley 23rd Annual Global Healthcare Conference2025-09-08T07:45:00
2025 Wells Fargo Healthcare Conference2025-09-04T13:30:00
Halozyme Therapeutics Inc Second Quarter Earnings Conference Call for 20252025-08-05T16:30:00
Halozyme Therapeutics Inc Second Quarter Earnings Results for 20252025-08-05T00:00:00
Goldman Sachs 46th Annual Global Healthcare Conference 20252025-06-09T10:00:00
BofA Securities 2025 Healthcare Conference2025-05-13T16:20:00
Halozyme Therapeutics Inc First Quarter Earnings Conference Call for 20252025-05-06T16:30:00
Halozyme Therapeutics Inc First Quarter Earnings Result for 20252025-05-06T00:00:00
Halozyme Therapeutics Inc Annual General Meeting for 20252025-05-01T08:00:00
TD Cowen 45th Annual Healthcare Conference2025-03-05T11:50:00
Halozyme Therapeutics Inc Fourth Quarter Earnings Conference Call for 20242025-02-18T16:30:00
Halozyme Therapeutics Inc Fourth Quarter Earnings Result for 20242025-02-18T00:00:00
Halozyme Therapeutics Inc Annual Report for 20242025-02-18T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.